Rigel Pharmaceuticals
RIGL
About: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Employees: 164
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
48,650% more call options, than puts
Call options by funds: $975K | Put options by funds: $2K
25% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 36
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
2% more funds holding
Funds holding: 123 [Q1] → 125 (+2) [Q2]
4% more capital invested
Capital invested by funds: $250M [Q1] → $260M (+$10.1M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0.14% less ownership
Funds ownership: 77.84% [Q1] → 77.7% (-0.14%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Cantor Fitzgerald
Kristen Kluska
|
$32
|
Neutral
Maintained
|
6 Aug 2025 |
Financial journalist opinion
Based on 4 articles about RIGL published over the past 30 days